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prognostic indicators, so that aggressive management could be
initiated at the earliest.
Methods: It is a prospective descriptive study conducted in the
Kerala InstituteofMedical Sciences, over a 21monthperiod from1st
June 2012. 271 consecutive patients with NYHA class 3 or 4 with
various etiology of heart failure were identified. The patients
belonged to Valvular heart diseases, Cardiomyopathies, congenital
heart diseases, thyrotoxicosis, Cor pulmonale and hypervolemia
due to renal failure. Patientswithnewonsetmyocardial infarctions,
acute inflammatory conditions and septicemia were excluded.
Results: Of the 271 patients, 203 (75 %) were males and 68(25%)
were females. 184(67.99%) patients had systemic hypertension.
171(63.1%) patients had coronary artery disease. 28(10.3%) pa-
tients had dilated cardiomyopathy and 26 (9.59%) had valvular
heart disease. 21(7.7%) had chronic rheumatic heart disease.
Among them mitral valve disease was present in 16(6.27%) and
combination of mitral and aortic valve were 4(1.47%). 3 (1.1%)
patients had myxomatous disease of the mitral valve and only
2(0.73%) with degenerative aortic valve disease.18(6.6%) had
restrictive cardiomyopathy , 8(3.0%) had cor pulmonale with right
heart failure . 6( 2.2%) patients had congenital heart disease.
5(1.8%) patients had chemotherapy induced cardiomyopathy
(Doxorubicin and Adriamycin) . 4(1.5%) patients had primary
pulmonary hypertension , while 2(0.7%) patients has tachycardia
induced cardiomyopathy.
71(26.20%) had chronic kidney disease, 170(62.7%) were diabetic,
44(16.24%) were hypothyroid . 110(41.33%) patients were smokers
with ex smokers.
Sinus rhythm was present in 196 (72%) patients , 43 (16%) pa-
tients had atrial fibrillation, 20 (7%) had left bundle branch block, 4
(3%) had right bundle branch block and 8 ( 2%) with ventricular
tachycardia. Cerebro vascular accident was found in 28(10.5%)
patents ,in which 26 (9,5%) had emboli stroke and 2 (0.7%) had
hemorrhagic stroke. In patients with cerebro vascular accident ,
majority were coronary artery disease with severe left ventricular
dysfunction, dilated left ventricle (LV end diastolic diameter +_6.5
cm) and were in sinus rhythm 19(7%).
Average hospital stay was 7(+_4) days, maximum duration of
stay was 45 days, Prolonged stay was majority with heart failure
and renal failure. 10 (3.6%) patients required invasive ventilatory
support and 12(4.4) required non-invasive ventilatory support. 30
(11.2%) patients were readmitted within 30 days of discharge and
17( 7%) patients readmitted within 90days.
Mortality in this group of patients were 31 (11.5%) when we
followed up to 21months andmajority were in the age between 70
-79 (4.8%). Major cause of death 20(7.3%) was due to coronary ar-
tery disease. Death due to chronic rheumatic heart disease and
congenital heart disease were 3(1.1%), idiopathic dilated cardio-
myopathy and primary pulmonary hypertension were 2(6.4%) and
due to hypertrophic cardiomyopathy was 1(0.3%).
Conclusion: Heart failure is a multi-faceted syndrome with mul-
tiple etiologies. We found that systemic hypertension contributes
to heart failure 67.99% of patients and ischemic heart disease
contributes to 63.1% of patients. Diabetes was the commonest co
morbidity of heart failure in our study.
Echocardiographic profile of patient with diabetic
cardiomyopathy
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Background: Diabetic cardiomyopathy refers to a disease process
which affects the myocardium in diabetic patients causing a wide
range of structural abnormalities causing diastolic and systolic
dysfunction or a combination of these in the absence of coronary
artery disease and hypertension. In our study we tried to evaluate
echocardiographic profile of patient with diabetic cardiomyopa-
thy and its correlation with glycemic control.
Methods: In our study we evaluated 25 patient of diabetes with
clinical features of heart failure with normal epicardial coronaries
& without history of hypertension. We evaluated echocardio-
graphic feature and pattern of systolic and diastolic dysfunction &
its correlation with glycemic control in patient of diabetic
cardiomyopathy.
Results: In our study all 25 patient were having diastolic
dysfunction while systolic dysfunction was found in 5 patients.
Out of the patients with diastolic dysfunction, 7 patients were
having grade 1 diastolic dysfunction, 6 were having grade 2 dia-
stolic dysfunction, 9 having grade 3 diastolic dysfunction and 3
having grade 4 diastolic dysfunction. While out of 5 patient of
systolic dysfunction 3 were having severe systolic dysfunction EF
< 30% and 2were havingmoderate systolic dysfunction EF 30-45%.
Higher grades of systolic and diastolic dysfunction were asso-
ciated with poor glycemic control. Out of 25 patients, only 7 pa-
tients were having good glycemic control while 18 patients were
having poor glycemic control.
Conclusion: Most of the patients of diabetic cardiomyopathy have
diastolic dysfunction & higher grades of systolic and diastolic
dysfunction were associated with poor glycemic control.
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Aim: The aim of this study is to compare the safety and efficacy of
levosimendan and dobutamine in patients with acute decom-
pensated heart failure.To compare the intensive care unit and
hospital stay between levosimendan and dobutamine groups.
Methods: A total of 30 consecutive patients hospitalized for acute
decompensated heart failure, LVEF30% were included in the
study. Patients were randomized 1:1 to either dobutamine (mini-
mum dose 5 mg kg-1 min-1) or levosimendan bolus (6mg kg-1) fol-
lowed by a infusion dose of levosimendan (0.1 mg kg-1min-1)for 48
hrs. Both treatment groups also received standard care.Effects on
haemodynamics were studied.The symptoms of dyspnea and fa-
tigue were evaluated by the patient and the physician at baseline
and after 48 hours.
Results: After 48 hrs increase in stroke volume [29% over baseline
for levosimendan compared with a 22% for dobutamine, p¼0.05]
and PCWP-lowering effect of levosimendan (28% decrease over
baseline for levosimendan compared with a 13% decrease for
dobutamine, p¼0.03) is significant. Intensive care unit stay in lev-
osimendan group is 1 day shorter than that of the standard treat-
ment group. Clinical symptoms of dyspnea and fatigue tended to
improvemorewith levosimendan than they didwith dobutamine.
Levosimendan group was associated with lesser arrhythmias.
Conclusions: Compared with dobutamine, a significantly higher
proportion of levosimendan patients experienced haemodynamic
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improvement with a clear increase in cardiac output and decrease
in PCWP. Levosimendan was associated with significantly
improved dyspnea and a trend towards improved fatigue. Inten-
sive care unit stay in levosimendan group is 1 day shorter than
that of the standard treatment group. This shows that the hos-
pitalization costs may be reduced by adopting levosimendan
treatment.
Evaluation of the role of multiple biomarkers in
short term prognosis of heart failure patients
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Background: The aim of the study was to evaluate the role of
multiple biomarkers in short term prognosis of heart failure
patients.
Methods: One hundred cases of heart failure diagnosed by Fra-
mingham’s criterion were taken up. Detailed history, clinical ex-
amination and echocardiographic analysis were done in each
patient. On the day of admission BNP, cTNT, cystatin C and NGAL
levels were estimated. Based on level of each biomarkers, the
patients were divided in two groups for prognostication purpose
for each biomarkers. BNP( > 300pg/ml vs < 300 pg/ml), cTNT ( >
0.03 ng/ml vs <0.03ng/ml and NGAL( > 140mg/l vs <140mg/l) Pa-
tients were followed up for ten days. Improvement or deteriora-
tion in symptoms and NYHA class were noted. Mortality if any
was also noted.
Results: It was observed that there is positive correlation between
clinical deterioration/ mortality and individual levels of BNP,
cTNT and cystatinC based on pre selected cut off value. Combi-
nation of BNP, cTNT and cystatin C all three levels above the cut
off value was associated with 62% of patients showing deteriora-
tion compared to 16% in all these below cut off. Similarly, patients
with combined BNP and cystatin C elevation showed 55% vs 23 %
and BNP and cTNT combined showed 60% vs 28% deterioration in
clinical symptoms.
Conclusions: Combination of BNP, cTNT and Cystatin C is better in
predicting short term outcome in patients of heart failure than
individual biomarkers.
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Department of cardiology, L.P.S Institute of Cardiology, Kanpur, India
Background: There is growing evidence that anaemia is common
in CHF and may contribute to the high morbidity and mortality
associated with this condition. However, considerable disagree-
ment exists about the prevalence of anemia in CHF patients, with
prevalence rates varying from 9.9% to 55.6%.
Objective: To find the Prevalence of Anaemia in chronic heart
failure and Contribution of Iron deficiency and Renal dysfunction
as underlying cause.
Methods: We studied 200 patients. All the patients were NYHA
class III or IV, 82% being class IV. Haemoglobin concentration of 11
g/dl or less was selected as our cut-off for anaemia. This group
was further subdivided into microcytic, normocytic, and macro-
cytic anaemia. In each of these groups it was noted if any patients
had renal impairment (creatinine >1.5mg/dl) and whether ferritin
was low (<15mcg/l).
Results: Seventy of the 200 patients (35%) selected had a mean
haemoglobin concentration of < 11 g/dl. Of these 70 patients,
20(28.6%) were microcytic, 41(58.6%) were normocytic and
9(12.8%) were macrocytic. In microcytic group, ferritin was low in
12(17.1%) and renal impairment were in 5(7.1%) patients. In nor-
mocytic group, ferritin was low in 7(10%) and renal impairment
were in 23(32.8%) patients. Inmacrocytic group, ferritin was low in
2(2.8%) and renal impairment were in 4 (5.7%) patients. As a
whole, renal impairment was present in 32 patients (45.7%) and
low ferritin was present in 21(30%) patients. The prevalence of
anemia increased from 17.72 % in thosewith a serum creatinine of
< 1.5 mg/dl to 87.5% in those with a serum creatinine of >2.5 mg%.
Conclusion: Anemia is a common finding in patients hospitalized
with CHF and significant numbers of anaemic CHF patients have
some degree of renal insufficiency or iron deficiency.
Management and outcome of anthracycline
cardiomyopathy
A.A. Dhir, S.P. Sawant, A. Daddi
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Background: The gain in life expectancy due to anthracycline
therapy might be countered by increased mortality due to car-
diotoxicity. The natural history of anthracycline induced cardio-
myopathy (AC-CMP) , remains poorly defined.
Objective: To study clinical profile of patients with AC-CMP and
response to heart failure (HF) therapy.
Methods: This is an analysis of prospectively collected data of
patients with a left ventricular ejection fraction (LVEF) 50 % due
to AC-CMP seen at a tertiary cancer centre in India .Patients with a
minimum follow up of 6 months, a baseline 2Decho,and at least
three 2Dechos after diagnosis of AC-CMP were included. De-
mographic details, comorbidities, cancer diagnosis and treatment
details including dose of anthracycline, treatment for CMP and
response to treatment (ACE inhibitors, beta blockers and or
digoxin) were recorded. Patients were considered responders and
nonresponders according to recovery in LVEF. Univariate and
multivariate analysis of effect of predictor variables on response
to treatment was done. Analyses were performed using PASW
software package (version 18).
Results: 55 patients newly diagnosed with AC-CMP were regis-
tered in 2010-2012. The median dose of doxorubicin was 300mg/
m2. Seven patients had received doxorubicin <¼ 180 mg/m2. Nine
patients (16.4%) presented with grade 4 cardiotoxicity and two
patients (3.6%) with grade 5. Median duration from last dose of
chemotherapy to development of AC-CMP was 5 months. The
median follow up duration was 15 months. 30 (54.5%) were re-
sponders. Age, co morbidities, mediastinal/left chest radiation,
doxorubicin dose, time to development of AC CMP did not affect
the response to treatment in univariate analysis. There was a
higher chance of non response in patients who received doxoru-
bicin more than 200mg/m2 (37%) and patients with grade 4
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